Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study.

Authors

Forschner A1, Battke F2, Hadaschik D2, Schulze M3, Weißgraeber S2, Han CT2, Kopp M2, Frick M2, Klumpp B4, Tietze N5, Amaral T6,7, Martus P8, Sinnberg T6, Eigentler T6, Keim U6, Garbe C6, Döcker D2,3, Biskup S2,3.
  1. Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Liebermeisterstr. 25, 72076, Tuebingen, Germany. andrea.forschner@med.uni-tuebingen.de.
  2. Center for Genomics and Transcriptomics (CeGaT) GmbH, Tuebingen, Germany.
  3. Practice for Human Genetics, Tuebingen, Germany.
  4. Institute for Radiology, Rems-Murr-Kliniken, Winnenden, Germany.
  5. Institute for Radiology, University Hospital Tuebingen, Tuebingen, Germany.
  6. Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Liebermeisterstr. 25, 72076, Tuebingen, Germany.
  7. Portuguese Air Force Health Care Direction, Lisbon, Portugal.
  8. Institute for Clinical Epidemiology and applied Biostatistics (IKEaB), Tuebingen, Germany.